Nippon Boehringer Ingelheim Begins Promoting Central Nervous System Drugs Lendormin and Bi-Sifrol Via MR-Kun Information Service.Tokyo, Japan, Feb 16, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Nippon Boehringer Ingelheim announced on February 16 that it has begin providing information on Lendormin and Bi-Sifrol, its two core products in the field of central nervous system (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) disease, through MR-Kun, an information service available on m3.com, So-net M3's portal site exclusively designed for medical professionals. Lendormin is a sleep inducer inducer /in·duc·er/ (in-dldbomacs´er) a molecule that causes a cell or organism to accelerate synthesis of an enzyme or sequence of enzymes in response to a developmental signal. in·duc·er n. and Bi-Sifrol is an agent for treating Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . Specifically, Nippon Boehringer Ingelheim has begun broadcasting the CNS Times program that features useful information on the two products and treatments of sleep disorder and Parkinson's disease. Through these means, the company aims to raise the profiles of Lendormin and Bi-Sifrol in Japan. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion